Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1644 1646
This examiner grants 53% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17343543 | MODIFIED ANTIBODY FCS AND METHODS OF USE | Non-Final OA | Genentech, Inc. |
| 18063459 | ANTIBODIES BINDING TO CD3 AND PLAP | Non-Final OA | Hoffmann-La Roche Inc. |
| 17818854 | METHODS OF INCREASING RESPONSE TO CANCER RADIATION THERAPY | Non-Final OA | The Trustees of the University of Pennsylvania |
| 18818268 | ANTIBODIES WITH FC MODIFICATIONS AND METHODS OF USING THE SAME | Non-Final OA | The General Hospital Corporation |
| 17254392 | CHIMERIC ANTIGEN RECEPTORS TARGETING CD37 AND CD19 | Final Rejection | The General Hospital Corporation |
| 18546302 | CUSTOMIZED CHIMERIC ANTIGEN RECEPTOR POLYPEPTIDES | Non-Final OA | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE INC. |
| 18052172 | METHODS OF TREATING CANCERS AND ENHANCING EFFICACY OF GPRC5DXCD3 BISPECIFIC ANTIBODIES | Non-Final OA | Janssen Biotech, Inc. |
| 17825244 | ANTI-IDIOTYPIC ANTIBODIES AGAINST ANTI-CD79B ANTIBODIES | Non-Final OA | Janssen Biotech, Inc. |
| 18278784 | TARGETING CONJUGATES WITH THERAPEUTIC AGENTS AND OLIGONUCLEOTIDES AND USES THEREOF | Non-Final OA | Allygen Group |
| 18258189 | ANTIBODIES AGAINST INTEGRIN ALPHA 11 BETA 1 | Non-Final OA | MOMENTA PHARMACEUTICALS, INC. |
| 17783548 | VERSATILE STRATEGY FOR COVALENT GRAFTING OF BIOMOLECULES TO CRYOGELS | Final Rejection | Stichting Radboud universitair medisch centrum |
| 17429288 | ANTIBODIES RECOGNIZING TAU | Non-Final OA | PROTHENA BIOSCIENCES LIMITED |
| 17769160 | PROTEINS BINDING NKG2D, CD16 AND FLT3 | Final Rejection | Dragonfly Therapeutics, Inc. |
| 18020577 | AFFIBODY-CYTOTOXIN CONJUGATE FOR ACTIVE TARGETED THERAPY OF TUMORS, NANOPARTICLE THEREOF, PREPARATION METHOD THEREOF AND APPLICATION THEREOF | Non-Final OA | SHANGHAI JIAOTONG UNIVERSITY |
| 17749824 | Modified Cell Expressing Therapeutic Agent and Uses thereof | Final Rejection | Innovative Cellular Therapeutics Holdings, Ltd. |
| 17295364 | Modified Cell Expressing Therapeutic Agent and Uses thereof | Final Rejection | Innovative Cellular Therapeutics Holdings, Ltd. |
| 17618849 | P2X7 RECEPTOR TARGETED THERAPY | Non-Final OA | BIOSCEPTRE (AUST) PTY LTD |
| 17295010 | IL-2 DEPENDENT NK-92 CELLS WITH STABLE FC RECEPTOR EXPRESSION | Non-Final OA | NantKwest, Inc. |
| 17320712 | METHODS FOR TREATING CANCER WITH MANUFACTURED T CELLS | Non-Final OA | RAPA THERAPEUTICS, LLC |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy